Hartley AE

ORCID: 0000-0003-4932-1588 · 1 paper in corpus

meta-analysis 2023

Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization

Arthritis & rheumatology (Hoboken, N.J.) ·doi:10.1002/art.42538

OBJECTIVE: In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. METHODS: A genome-wide association study meta-analysis was…